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It was found that enzyme from a microbial strain, Monocillium spp. ATCC 20621, catalyzed the oxidative 
reaction of rifamycin B to form rifamycin 0. The identification of the reaction products suggested that 
the reaction proceeded by the oxidative cyclization of rifamycin B to give rifamycin 0, which 
spontaneously hydrolyzed to rifamycin S in neutral aqueous milieu. The characteristic of the enzyme was 
different as compared with that of other polyphenol oxidases such as lactase. It is proposed that this new 
type of enzyme be classified into a subgroup EC 1.10.3.6 with a trivial name rifamycin B oxidase. 
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1. INTRODUCTION 
Studies on the biosynthesis of rifamycin B 
indicated that rifamycin SV is the precursor of rifa- 
mycin B in Nocardia mediterranei culture. 
[r4C]Rifamycin SV was converted in high yield 
into labelled rifamycin B by either growing culture 
or by washed mycelia of this microorganism [1,2]. 
It was supported by the isolation of a mutant of 
N. mediterranei producing rifamycin SV [3]. In the 
final step of rifamycin B biosynthesis, rifamycin 
SV or its oxidized form, rifamycin S, was conver- 
ted into rifamycin B, but it is not known whether 
the intermediate rifamycin 0 was involved or not. 
We attempted to determine other microbial 
species which could catalyze the conversion of rifa- 
mycin B to rifamycin 0 or rifamycin S, which is 
the reverse reaction of rifamycin B biosynthesis, 
and were able to isolate two kinds of Fungi Im- 
perfecti, Humicola spp. and Monocillium spp., 
which are now assigned the no. ATCC 20620 and 
20621, respectively. 
Here, this new type of enzyme of Monocillium 
spp. ATCC 20621 was purified and enzymic charac- 
teristics, including substrate specificity, were com- 
pared with those of other similar enzymes known. 
2. MATERIALS AND METHODS 
2.1. Materials 
All the chemicals including NAD+, NADP+, 
FAD, pyrogallol and resorcinol were purchased 
from Sigma, Bacto-beef and yeast extract were ob- 
tained from Difco. Thin-layer chromatography 
sheet (no. 13181) was purchased from Eastman. 
Rifamycin B was prepared from culture broth of 
N. mediterranei as in [4]. Rifamycin 0, refamycin 
S and rifamycin SV were prepared by the improved 
synthetic method [5]. Diethylaminomethyl rifa- 
mycin SV was synthesized from rifamycin S by 
Mannich reaction [6] and 3-formylrifamycin SV 
was prepared by the oxidative cleavage of DEAM- 
rifamycin SV [7]. 
2.2. Enzyme preparation 
The microbial cells of Monocillium spp. ATCC 
20621 were grown in a 28-1 jar fermentor (NBS 
model CMF-128, USA) with a working volume of 
15 1 with an agitation speed of 300 rev./min and an 
aeration rate of 1.5 vvm at 30°C for 4 days. The 
culture medium was composed of Bacto-beef 
(1 .O%), yeast extract (1 .O%) and dextrose (1 .O%). 
All the purification steps were conducted in a 
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cold room (5’C) unless otherwise stated. Cultured 
fungal mycelium pellets were separated by filtra- 
tion and ground with Jank-Kunkel Ultra-Turrax. 
Wet cell cake (45 g) containing 1800 units of en- 
zyme activity was recovered from 11 culture broth 
with 99% recovery of enzyme activity. The cell 
cake was homogenized with acid-washed glass 
beads (75-150 PM) in 500 ml of phosphate buffer 
(50 mM, pH 7.0). Protein precipitates with active 
enzyme fraction, appearing in 30-70% ammonium 
sulfate, were collected from the supernatant. The 
precipitates were redissolved in 10 mM phosphate 
buffer (pH 7.0) followed by ultra-~ltration with 
Amicon millipore filter. The crude enzyme solu- 
tion (2.0 g) was applied to a DEAE-cellulose 
column (4 x 40 cm) and equilibrated with 20 mM 
phosphate buffer (pH 7.2). The column was then 
washed with the equilibration buffer at a flow rate 
40 ml/h until &SO was ~0.05, and followed by 
linear NaCl gradient elution (O-O.5 M). The active 
fractions were pooled and ultrafiltered. The sam- 
ple was applied on the Sephadex G-100 column 
(2 x 50 cm) and equilibrated with 10 mM phos- 
phate buffer (pH 7.0). Active fractions were col- 
lected and used for other experiments. 
2.3. Assay methods 
Two different methods were used for the deter- 
mination of rifamycin B oxidase activity: Firstly, 
the enzyme activity was measured by the spectro- 
photometric method. The enzyme solution was 
added to 2 ml rifamycin B (2 mM phosphate buf- 
fer, pH 7.8). After incubation for 15 min at 40°C 
with vigorous stirring, usine a star-shaped mag- 
netic bar (Nalge), the reaction mixture was boiled 
for 5 min in a water bath to stop the enzyme reac- 
tion with simultaneous hydrolysis of rifamycin 0 
to rifamycin S. The hydrolysis of rifamycin 0 was 
completed in a given assay condition as visualized 
in thin-layer chromatography (TLC). The reaction 
mixture was cooled with running water and diluted 
2-fold with 0.1 M phosphate buffer (pH 7.8). The 
absorbance of rifamycin S in the reaction mixture 
was measured at 525 nm (Et2 = 68) in phosphate 
buffer (pH 7.8). One unit of enzyme activity is 
defined as the amount of enzyme oxidizing 1 rmol 
of rifamycin B/h. The enzyme activity was also 
measured by the consumption of dissolved oxygen 
with Gilson Model 5/6H oxygraph at 37°C with 
various substrates. 
2.4. Electrophoretic analysis 
Electrophoretic analysis on 7.5% acrylamide gel 
(0.75 x 8.5 cm) was performed in Tris-glycine 
buffer (pH 8.3) as in [S]. For the activity-staining 
of rifamycin B oxidase activity, the gel was im- 
mersed in 2 mM rifamycin B solution for 20 min 
and incubated in 0.1 M phosphate buffer (pH 7.8) 
containing 50% glycerol for 1 h at 30°C. 
2.5. TLC method 
Eastman Chromagram sheet no. 13181 was 
used with a developing solvent system of chloro- 
form-acetone (1: 1). During the enzyme reaction, 
in 2 mM rifamycin B (0.1 M phosphate buffer, 
pH 7.5) with 25 units of the enzyme, 5 ml aliquots 
were pooled, acidified with d-HCl, and extracted 
with 1 ml ethyl acetate. The organic layer was 
pooled and developed twice on TLC. 
3. RESULTS 
The result of a typical purification procedure for 
the enzyme is shown in table 1. About 95% of the 
Table 1 
Purification steps of rifamycin B oxidase from ~O~oei~Ii~~ spp ATCC 20621 
Purification Total Total act. Spec. act. Yield Purification 
step protein (units) (units/mg (Too) (-fold) 
(mg) protein) 
Homogenization 2638 5540 2.1 100 1.0 
Fractionation by ~monium sulfate 620 4432 7.14 80 3.4 
DEAE-cellulose 45.4 3601 79-3 65 37.8 
Sephadex G- 100 8.11 1551 191.2 28 91.0 
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Fig. 1. Polyacrylamide gel electrophoresis of purified 
enzyme and activity staining. The red colour of rifa- 
mycin S, the hydrolyzed product of rifamycin 0 at this 
pH easily visualized the location of active enzyme band 
(1A). The protein stained with 0.5% amido block 10B 
appeared as a single band (1B). 
initial enzyme activity was recovered by homogeni- 
zation with glass beads. During DEAE-cellulose 
column chromatography, the active fractions were 
eluted with NaCl solution in a gradient between 
0.15 -0.25 M. Gel filtration on Sephadex G-100 
showed the coincidence of the protein and the ac- 
tivity band suggesting that the enzyme was nearly 
pure. Analysis by polyacrylamide gel electrophore- 
sis confirmed the purity of the enzyme obtained by 
the present purification procedure. The location of 
the enzyme was indicated by its coincidence with a 
band stained for activity (fig. 1). 
Thin-layer chromatography on a time course of 
enzyme reaction confirmed the identity of the reac- 
tion products (fig. 2). Rifamycin S (purple, Rf 0.7) 
and rifamycin 0 (pale yellow, Rf 0.8) were identi- 
fied along with unconverted rifamycin B (yellow, 
Rf 0.1) at the initial stage of enzyme reaction. Rifa- 
Fig. 2. Identifi~tion of reaction products by thin-layer 
chromatography. (la) 5 min; (1 b) 30 min; (Ic) 2 h; (Id) 
reduced with ascorbic acid after reaction for 30 min; (le) 
standards of rifamycin derivatives. Rf = 0.1, rifamycin 
B (yellow); I?f = 0.25, rifamycin SV (yellow); Rf = 0.7, 
rifamycin S (purple); Rf = 0.8, rifamycin 0 (pale yellow); 
(If) shows the reaction products, the enzyme reaction 
being carried out at pH 5.0 (0.1 M acetate buffer). 
Apparent inhibition by NADH is tested. (2a) Standard 
samples rifamycin 0 + rif~ycin S; (2b) rifamycin 0 + 
NADH; (2~) rifamycin 0 + mercaptoethanol; (2d) rifa- 
mycin 0 + cysteine. 
Table 2 
Effect of electron acceptors and donors on the rifamycin 
B oxidase activity 
Electron donor or 
acceptor 
Cont. (mM) Enzyme activity 
(pmoI/h) 
None 0.0 6.8 
NAD+ 0.5 6.5 
NADP+ 0.5 6.8 
FAD 0.5 7.1 
NADH 0.5 2.3 
NADPH 0.5 2.3 
Cysteine 20.0 4.2 
Mercautoethanol 150.0 0.85 
mycin 0 and rifamycin B spots were attenuated 
with the intensification of the rifamycin S spot as 
the reaction proceeded. 
The effect of various electron acceptors such as 
NAD+, NADP+ and FAD on the enzymatic oxida- 
tion of rifamycin B was examined and the results 
are shown in table 2. Experimental results indi- 
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cated that the enzyme can be classified as an oxi- 
dase, not a kind of dehydrogenase since there was 
no requirement of electron acceptor other than 
oxygen. 
NADH and NADPH showed an apparent inhi- 
bition on the enzyme, and it was further examined 
by thin-layer chromatography. The results indi- 
cated that the inhibition mode was an artifact since 
the reaction product rifamycin 0 was found to be 
reduced to the initial substrate rifamycin B in the 
presence of such electron donors. It was also con- 
firmed by the finding that the apparent inhibition 
of enzyme activity in the presence of the reducing 
agents such as cysteine and mercaptoethanol was 
accompanied with the reduction of rifamycin 0 to 
rifamycin B (fig. 2). 
Substrate specificity of the enzyme was com- 
pared with that of lactase by the relative oxidation 
rates of various rifamycin derivatives and other 
phenolic compounds (table 3). The enzyme rapidly 
oxidized hydroquinone and rifamycin B, while lac- 
case showed relatively low activity on those com- 
pounds. This enzyme oxidized hydroquinone and 
rifamycin B rapidly, while lactase showed rela- 
tively low activity on those compounds. This 
Table 3 
Comparison of the substrate specificity of rifamycin B 
oxidase and lactase 
Substrate= Relative reaction rate ((IJo)’ 
Rifamycin B Laccaseb 
oxidase 
Rifaxnycin B 100.0 3.5 
Rifamycin SV 54.4 29.7 
DEAE-rifamycin SV 0.0 - 
3-Formylrifamycin SV 2.3 - 
p-Hydroxyphenoxyacetic acid 0.3 _ 
p-Hydroquinone 260.5 14.0 
Pyrogallol 57.8 100.0 
Catechol 13.6 20.5 
Resorcinol 0.0 2.0 
a The concentration of all the substrates used was 2 mM 
b Crude preparation of lactase was obtained by am- 
monium sulfate precipitation of the culture filtrate of 
Pleurotus ostriatus 
’ Enzyme activity was measured with oxygraph (Gilson 
model 5/6H) 
enzyme also oxidised rifamycin SV, 3-formylrifa- 
mycin SV, pyrogallol and catechol. Resorcinol and 
the Mannich derivative of rifamycin SV (3-diethyl- 
aminomethyl rifamycin SV) were not attacked at 
all. p-Hydroxyphenoxyacetic acid resembling the 
reactive moiety of rifamycin B gave very low 
activity with the enzyme. 
The UV-visible absorption spectrum of the 
purified enzyme exhibited a typical protein absorp- 
tion spectrum with a maximum peak at 280 nm 
with no significant absorption in the visible region. 
Thus the enzyme seemed to contain no chromo- 
phogenic moiety such as flavins, heme of Cu3+. 
The effect of various metal ions on the enzyme 
activity was studied, using rifamycin B as a sub- 
strate. The enzyme activity was neither inhibited by 
Ag+ or Hg2+, nor activated by Cu2+. Other metal 
ions such as Ca’+, Mg2+, Fe3+, Fe2+, Co2+, Mn’+, 
Zn2+ and Mo6+ did not affect their enzyme activi- 
ty. The addition of a metal chelating agent such as 
EDTA caused no marked inhibition of the enzyme 
activity. 
4. DISCUSSION 
The newly discovered enzyme catalyzed the oxi- 
dation of rifamycin B to rifamycin 0 which was 
subsequently hydrolyzed to give rifamycin S de- 
pending upon the pH value of the reaction solu- 
tion. Isolation and identification of the enzyme 
reaction product by thin-layer chromatography and 
instrumental analysis, together with the balance 
study of the reaction, have led to the following 
reaction scheme (fig. 3). 
The studies on the enzymatic characteristics 
showed that this enzyme had quite different 
properties as compared with other similar enzymes 
such as catechol oxidase (EC 1.10.3.1), lactase 
(EC 1.10.3.2), ascorbate oxidase (EC 1.10.3.3), 
o-aminophenol oxidase (EC 1.10.3.4) and 3-hyd- 
roxyanthranilate oxidase (EC 1.10.3.5) using di- 
phenols and related compounds as electron donors, 
and oxygen as an electron acceptor [lo]. 
The substrate specificity of the enzyme was also 
different to that of the lactase from Pleurotus 
ostriatus, and to other sources [1 l-131. First of all, 
this enzyme is neither a cuproprotein nor a flavo- 
protein. From table 2, the metal ion effect, and the 
absorption spectrum of the protein, this enzyme 
appears to contain no flavins, heme, non-heme 
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Rifamycin B Rifamycin 0 Rifamycin S 
Fig. 3. Proposed mechanism of rifamycin B oxidase action. Hydrogen peroxide was detected during enzyme reaction 
with p-Hydroquinone as a substrate by peroxidase-o-dianisidine method [9]. 
iron nor other metal ions as co-factors, nor the -SH 
group in the active site of the enzyme. 
We proposed that this new type of enzyme be 
assigned to subgroup EC 1.10.3.6 (acting on di- 
phenols and related substances as electron donors, 
and on oxygen as an electron acceptor) with the 
trivial name rifamycin B oxidase. 
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